Di Chen1, Q Ping Dou. 1. Wayne State University, The Prevention Program, Barbara Ann Karmanos Cancer Institute, Department of Pathology, School of Medicine, Detroit, Michigan, USA.
Abstract
BACKGROUND: The conventional approach toward anticancer drug development is a time-consuming and expensive procedure. OBJECTIVE/ METHODS: One approach to expedite this process and achieve more affordable means is to discover new applications of existing drugs, since their pharmacokinetics and pharmacological profiles are well known. RESULTS: Our encouraging findings in recent studies reveal anticancer activities of several copper-binding ligands including disulfiram (an antialcoholism drug), clioquinol (used to treat Alzheimer's and Huntington's diseases) and diethyldithiocarbamate (an agent for HIV-1 infection treatment). CONCLUSION: These in vitro and in vivo studies have demonstrated that these archaic drugs can target and react with tumor cellular copper, forming complexes that act as potent proteasome inhibitors and apoptosis inducers.
BACKGROUND: The conventional approach toward anticancer drug development is a time-consuming and expensive procedure. OBJECTIVE/ METHODS: One approach to expedite this process and achieve more affordable means is to discover new applications of existing drugs, since their pharmacokinetics and pharmacological profiles are well known. RESULTS: Our encouraging findings in recent studies reveal anticancer activities of several copper-binding ligands including disulfiram (an antialcoholism drug), clioquinol (used to treat Alzheimer's and Huntington's diseases) and diethyldithiocarbamate (an agent for HIV-1 infection treatment). CONCLUSION: These in vitro and in vivo studies have demonstrated that these archaic drugs can target and react with tumor cellular copper, forming complexes that act as potent proteasome inhibitors and apoptosis inducers.
Authors: Martin Michaelis; Iduna Fichtner; Diana Behrens; Wolfram Haider; Florian Rothweiler; Andreas Mack; Jaroslav Cinatl; Hans Wilhelm Doerr; Jindrich Cinatl Journal: Int J Oncol Date: 2006-02 Impact factor: 5.650
Authors: J Yoshii; H Yoshiji; S Kuriyama; Y Ikenaka; R Noguchi; H Okuda; H Tsujinoue; T Nakatani; H Kishida; D Nakae; D E Gomez; M S De Lorenzo; A M Tejera; H Fukui Journal: Int J Cancer Date: 2001-12-15 Impact factor: 7.396
Authors: Andrea Sartore-Bianchi; Fabio Gasparri; Arturo Galvani; Linda Nici; James W Darnowski; Dario Barbone; Dean A Fennell; Giovanni Gaudino; Camillo Porta; Luciano Mutti Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou Journal: Breast Cancer Res Date: 2005-09-20 Impact factor: 6.466
Authors: Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou Journal: Curr Pharm Des Date: 2010-06 Impact factor: 3.116
Authors: Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle Journal: Antimicrob Agents Chemother Date: 2010-06-14 Impact factor: 5.191
Authors: Sarmad Sahiel Hindo; Michael Frezza; Dajena Tomco; Mary Jane Heeg; Lew Hryhorczuk; Bruce R McGarvey; Q Ping Dou; Cláudio N Verani Journal: Eur J Med Chem Date: 2009-05-24 Impact factor: 6.514
Authors: Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch Journal: Oncotarget Date: 2013-04